Jiangxi Jemincare Group, a biopharmaceutical company based in China, has announced that it has received clinical trial approvals for two of its Category 1 therapeutic biologics, JMB2004 and JYB1931. JMB2004, a monoclonal antibody (mAb), has been approved for clinical study in the United States for the treatment of sepsis and septic shock. Preclinical studies have demonstrated that JMB2004 can significantly alleviate sepsis symptoms and boost survival rates in animal models. The antibody exhibits lower immunogenicity and higher affinity compared to the reference antibody, offering advantages such as lack of toxic side effects, high safety, and a low administration frequency.
On the other hand, JYB1931 is a MASP-2-targeted mAb that has been cleared for study in China for the treatment of IgA nephropathy. Preclinical research data indicates that JYB1931 has a specific high affinity binding to MASP-2, nearly a hundred times superior to the fastest clinically progressing similar drugs. In human MASP-2 transgenic mice, JYB1931 exhibits a longer half-life and a higher maximum drug exposure concentration at the same dose. The drug can significantly reduce renal cell apoptosis induced by proteinuria.- Flcube.com
